Related Experiment Video
Updated: Apr 19, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.3K
Hypofractionated radiotherapy for prostate cancer
Nina-Sophie Hegemann1, Matthias Guckenberger2, Claus Belka3
1Department of Radiation Oncology, University Hospital Munich, Campus Grosshadern, Marchioninistr. 15, D-81377, Munich, Germany. Nina-Sophie.Hegemann@med.uni-muenchen.de.
Radiation Oncology (London, England)
|December 7, 2014
Summary
Hypofractionated external beam radiotherapy is increasingly popular for prostate cancer, offering therapeutic benefits due to the cancer's low alpha/beta ratio. Recent trials show promising tumor control with minimal late toxicity, enhancing patient convenience.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Prostate cancer treatment increasingly utilizes hypofractionated external beam radiotherapy.
- This approach is supported by evidence of prostate cancer's low α/β ratio compared to surrounding organs at risk.
- Hypofractionation offers benefits like reduced treatment time and improved patient convenience.
Purpose of the Study:
- To analyze recent clinical trials on hypofractionated radiotherapy for prostate cancer.
- To detail the rationale behind hypofractionation in prostate cancer therapy.
- To examine various therapeutic settings for hypofractionated treatment.
Main Methods:
- Review of contemporary randomized clinical studies.
- Analysis of treatment outcomes, focusing on tumor control and toxicity.
- Evaluation of the therapeutic rationale and clinical benefits.
Main Results:
- Contemporary trials report encouraging tumor control rates.
- Late toxicity has not significantly increased with hypofractionation.
- Older trials had limitations due to insufficient doses and non-standard target volumes.
Conclusions:
- Hypofractionated radiotherapy shows significant promise for prostate cancer treatment.
- The approach offers a favorable therapeutic window due to the tumor's radiobiological characteristics.
- Further research and analysis of clinical trials support its growing popularity and efficacy.
